Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment

NCT06381284 | Completed

• 1 other identifier: MG-001
• Study Type: observational
• Target: 215
• Locations: 1 country
• Sites: 1

Brief Summary

This is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The main study objective is to evaluate the feasibility of a social media recruitment campaign tied to a participant reported symptom survey and self-administered physical assessment tool to influence undiagnosed participants to seek care for suspected Myasthenia Gravis (MG).

Conditions

Myasthenia Gravis; Neuromuscular Manifestations; Neuromuscular Diseases

Keywords

Social Media; Myasthenia Gravis

Outcome Measures

Primary Outcomes (1)

• Social media recruitment feasibility

  Measure the engagement and feasibility metrics of the social media campaign

  Enrollment period (4-6weeks)

Secondary Outcomes (1)

• MG Exercise Assessment Tool validity

  1 year from time of enrollment

Other Outcomes (1)

• Time to diagnosis

  1 year from time of enrollment

Study Arms (1)

Participants with undiagnosed neuromuscular symptoms

Behavioral: Social media recruitment; Behavioral: Self-Assessment; Behavioral: Follow-up

Interventions

Social media recruitment BEHAVIORAL

Social media users exposed to a variety of paid social media advertisements as a recruitment tool for study enrollment

Participants with undiagnosed neuromuscular symptoms

Self-Assessment BEHAVIORAL

Eligible participants are asked to complete self-administered physical tests to assess inducible fatigue of specific muscle groups

Participants with undiagnosed neuromuscular symptoms

Follow-up BEHAVIORAL

Patients triaged based on their assessed risk of MG are asked to complete recommended follow-up with a clinician to determine presence of myasthenia gravis

Participants with undiagnosed neuromuscular symptoms

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult participants who have undiagnosed neuromuscular symptoms

You may qualify if:

• Reside within the 50 states of the United States at the time of enrollment
• Age 19 or older if reside in Nebraska or Alabama, Age 21 or older if reside in Mississippi, Age 18 years or older if reside in any other state
• Active email account
• Fluency in English (spoken / written), as demonstrated by the ability to read and sign the Informed Consent Form

You may not qualify if:

• Live in an overseas territory of the United States
• Inability or unwillingness to provide written informed consent
• Diagnosed myasthenia gravis
• Diagnosed multiple sclerosis
• Have speech impairment, eye/arm/leg weakness due to diagnosed brain cancer, or stroke

Sponsors & Collaborators

• ZS Associates: lead
• UCB Pharma: collaborator
• University of California, San Francisco: collaborator

Study Sites (1)

ZS Associates

Evanston, Illinois, 60201, United States

Location

Related Links

• Study landing page

MeSH Terms

Conditions

Myasthenia Gravis; Neuromuscular Manifestations; Neuromuscular Diseases

Interventions

Diagnostic Self Evaluation

Condition Hierarchy (Ancestors)

Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Paraneoplastic Syndromes; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Junction Diseases; Autoimmune Diseases; Immune System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and Procedures; Diagnosis

Study Officials

• Ananda Vishnu Pandurangadu, MD

  ZS Associates

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Senior Consultant

Study Record Dates

• First Submitted: April 18, 2024
• First Posted: April 24, 2024
• Study Start: March 28, 2024
• Primary Completion: March 3, 2025
• Study Completion: March 3, 2025
• Last Updated: March 25, 2025

Record last verified: 2025-03

Locations

US (1)